23 August 2018
Visiongain’s new report Global Stem Cell Technologies and Applications Market 2017-2027: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications indicates that the global stem cell technologies and applications market will see $17,768 million in spending in 2020.
The global stem cell technologies and applications market is expected to grow at a CAGR of 13.4% in the first half of the forecast period and CAGR of 10.5% in the second half of the forecast period. The market is expected to grow at a CAGR of 11.7% from 2016 to 2027. The market is estimated at $10,751 million in 2016 and $17,768 million in 2020.
The lead analyst of the report said: “In 2016, visiongain estimates that the total global stem cell and technologies and applications market reached revenues of approximately $10,751 million. We estimate that stem cell therapies accounted for 42.7% of the revenues in the market, whilst non-therapeutic applications accounted for 57.3%.
We believe that the US led the market for stem cell technologies and applications in 2016. This is largely due to the greater cost of HSCT, higher demand and provision of cord blood banking services, and higher stem cell research output in the US. The greater availability of funds also makes the USA stem cell market potentially more attractive to market players.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analysis of the global market of stem cell technologies and applications. The forecast is further segmented by application: Cancer treatment, Cardiovascular, CNS, Other Disease Area and Non-Therapeutic applications.
This report provides individual revenue forecast to 2027 for selected top products: MSC-100-IV (Mesoblast), Hearticellgram-AMI (Pharmicell), CardioRel (Reliance Life Sciences), Osteocel Plus (NuVasive), Trinity Evolution and Elite (Orthofix), CARTISTEM (MEDIPOST).
Moreover, this report provides analysis of the most promising pipeline therapies in each therapeutic segment. The 257-page report gives insights on regulatory environments and developments in the US, Japan, Europe and other leading countries as well as analysis of what drives and restrains the market.
In this brand new 257-page report you will receive 114 charts– all unavailable elsewhere.
The report Global Stem Cell Technologies and Applications Market 2017-2027: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications report will be of value to anyone who wants to better understand the Stem Cell Technologies and Applications Market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Stem Cell Technologies and Applications Market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.